# Selank Dosage in Research: Routes, Half Life & Protocols Studied > Selank dosage as documented in research only: the µg/kg ranges and routes used in studies, the 0.15% intranasal clinical formulation, half life, and protocols studied. No human dosing guidance. A research-context account of the doses, routes, half-life, and study protocols in the literature — not human dosing guidance. ## Read this first This page describes **Selank dosage** the way the studies describe it — what researchers gave to animals or to patients in supervised trials — and nothing more. It is not a how-to and not a recommendation, because Selank is not approved for human use. In plain terms: animal studies often used small amounts measured per kilogram of body weight, given either as a nasal dose or by injection; the Russian clinical formulation was a weak nasal solution used over a few weeks under medical supervision; and the intact peptide clears the body fast, in minutes, though its breakdown products may carry the effect a bit longer. Numbers below are reported from research records so you can understand the science. None of them tell anyone what to take. ## Selank dosage In research, Selank dosage is reported in study units, not consumer instructions. Animal studies frequently used 100-300 µg/kg given intranasally or systemically — for example, 300 µg/kg was the single dose used in the rat study that shifted 45 then 22 GABA-pathway genes [4]. In human research, the Russian clinical formulation was a 0.15% aqueous intranasal solution applied as nasal drops, given over multi-week courses (commonly around two to three weeks) as an alternative or adjunct to benzodiazepine therapy in generalized anxiety and anxiety-asthenic disorders [6][16]. These are documented research and clinical-trial parameters from a single-region evidence base; they are reported here for understanding only, and no human dose is recommended on this site. ## Selank nasal spray Intranasal delivery is the primary clinical route for Selank, and the reason it appears so often as a Selank nasal spray. The Russian clinical product was a 0.15% aqueous solution delivered as nasal drops [6], and the intranasal route is favored because it lets a peptide reach the central nervous system efficiently. In the community, the nasal route is also where the most common tolerability complaint shows up — mild nasal dryness, burning, or stinging, generally attributed to the liquid carrier rather than the peptide (see [Selank effects](/effects)). The route used in studies does not translate into a human dosing instruction here. ## Selank half life The Selank half life is short for the intact peptide. Reported plasma half-life of the intact heptapeptide is on the order of minutes, which fits the very common user report of a short per-dose effect. The design twist is that its metabolites retain biological activity, which is proposed to extend the functional duration of effect beyond what the parent peptide's clearance alone would predict. That "active metabolite" rationale is mechanistically plausible but not rigorously quantified in Western sources, and no rigorously validated human pharmacokinetic profile of Selank is published in mainstream Western literature [6]. The C-terminal Pro-Gly-Pro extension is what slows degradation relative to native tuftsin in the first place. ## Selank peptide protocol Where a Selank peptide protocol appears in the actual literature, it is a study design, not a user regimen. The clearest example is the Russian clinical work: intranasal Selank as a 0.15% solution over multi-week courses, used as an alternative or adjunct to benzodiazepine therapy in diagnosed, supervised patients [6][16]. Preclinically, protocols span intranasal, intraperitoneal, subcutaneous, and intravenous routes in rodents, with single-dose and repeated-dose designs depending on the question [4][7]. Notably, a rat study combined Selank with diazepam and found the combination most effective at reducing stress-induced anxiety [7] — a research finding about GABAergic interaction, not a co-administration suggestion. Any protocol described here is reported from research records only. ## Routes and stability in research Across the literature Selank has been studied intranasally (the primary clinical route in Russia), intraperitoneally and subcutaneously in rodents, and intravenously in rodent pharmacokinetic work. For handling, the peptide is typically supplied lyophilized (freeze-dried) for research, with reconstituted solutions kept refrigerated; its C-terminal Pro-Gly-Pro extension is the structural feature that slows enzymatic breakdown and underpins its usability. Because human pharmacokinetics are poorly characterized in mainstream literature and Selank is not FDA-approved, none of these route or stability notes constitute a usage instruction — they describe how studies were conducted, which is the only thing the evidence supports. --- A hopeful read of the Selank research, told honestly — editorial summaries of the published science, never medical advice.